Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Therapeutics symbols : Axsm save search
Axsome Therapeutics Highlights Innovative Neuroscience Portfolio at the American Academy of Neurology (AAN) 2024 Annual Meeting
Published: 2024-04-15 (Crawled : 11:00) - globenewswire.com
AXSM | $67.91 3.33% 3.22% 890K
|
Health Technology
|
| O: -3.37%
H: 0.83%
C: -0.76%
neurology meeting therapeutics
Axsome Therapeutics to Report First Quarter 2024 Financial Results on May 6
Published: 2024-04-10 (Crawled : 11:00) - globenewswire.com
AXSM | $67.91 3.33% 3.22% 890K
|
Health Technology
|
| O: -2.66%
H: 1.26%
C: 0.37%
first report therapeutics financial results
Axsome Therapeutics Initiates ENGAGE Phase 3 Trial of Solriamfetol for the Treatment of Binge Eating Disorder
Published: 2024-04-01 (Crawled : 11:00) - globenewswire.com
AXSM | $67.91 3.33% 3.22% 890K
|
Health Technology
|
| O: 0.32%
H: 0.0%
C: -3.52%
treatment trial therapeutics solriamfetol
Axsome Therapeutics Announces AXS-12 Achieves Primary Endpoint in the SYMPHONY Phase 3 Trial in Narcolepsy
Published: 2024-03-25 (Crawled : 11:00) - globenewswire.com
AXSM | $67.91 3.33% 3.22% 890K
|
Health Technology
|
| O: 3.64%
H: 0.35%
C: -7.48%
axs-12 narcolepsy symphony trial therapeutics
Axsome Therapeutics Announces Results of CRESCENDO Narcolepsy Patient Survey Demonstrating Unmet Needs in Treated Narcolepsy Type 1 Patients
Published: 2024-03-25 (Crawled : 11:00) - globenewswire.com
AXSM | $67.91 3.33% 3.22% 890K
|
Health Technology
|
| O: 3.64%
H: 0.35%
C: -7.48%
narcolepsy therapeutics results
Axsome Therapeutics Initiates PARADIGM Phase 3 Trial of Solriamfetol for the Treatment of Major Depressive Disorder
Published: 2024-03-19 (Crawled : 11:00) - globenewswire.com
AXSM | $67.91 3.33% 3.22% 890K
|
Health Technology
|
| O: 0.84%
H: 5.95%
C: 5.09%
treatment trial therapeutics solriamfetol
Axsome Therapeutics to Present at the Leerink Partners Global Biopharma Conference
Published: 2024-03-05 (Crawled : 12:00) - globenewswire.com
AXSM | $67.91 3.33% 3.22% 890K
|
Health Technology
|
| O: -0.45%
H: 0.86%
C: -1.58%
conference biopharma global therapeutics
Axsome Therapeutics to Present at the TD Cowen 44th Annual Healthcare Conference
Published: 2024-02-27 (Crawled : 12:00) - globenewswire.com
AXSM | $67.91 3.33% 3.22% 890K
|
Health Technology
|
| O: 0.75%
H: 2.12%
C: 1.3%
conference therapeutics
Axsome Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
Published: 2024-02-20 (Crawled : 12:00) - globenewswire.com
AXSM | $67.91 3.33% 3.22% 890K
|
Health Technology
|
| O: -8.42%
H: 3.52%
C: -4.54%
business year update therapeutics financial results
Axsome Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results on February 20
Published: 2024-01-23 (Crawled : 12:00) - globenewswire.com
AXSM | $67.91 3.33% 3.22% 890K
|
Health Technology
|
| O: 0.62%
H: 0.43%
C: -2.14%
report year therapeutics financial results
Axsome Therapeutics Provides Preliminary Fourth Quarter and Full Year 2023 Net Revenue and 2024 Anticipated Milestones
Published: 2024-01-04 (Crawled : 12:00) - globenewswire.com
AXSM | $67.91 3.33% 3.22% 890K
|
Health Technology
|
| O: 2.6%
H: 9.85%
C: 5.02%
year revenue therapeutics
Autism Spectrum Disorder Therapeutics Market to Grow at a Substantial Growth Rate During the Study Period (2019-2032), Assesses DelveInsight | Key Players in the Market - Otsuka, Jazz, MapLight, Vanda, ACADIA, AbbVie, Axial, Roche, Yamo
Published: 2023-12-19 (Crawled : 22:00) - prnewswire.com
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
|
| O: -0.39%
H: 1.49%
C: 0.32%
SUPN | $29.43 1.94% 1.9% 360K
|
Health Technology
|
| O: -0.11%
H: 0.82%
C: -2.31%
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: 0.21%
H: 0.0%
C: 0.0%
AXSM | $67.91 3.33% 3.22% 890K
|
Health Technology
|
| O: -0.46%
H: 0.0%
C: -4.03%
ACAD | $16.82 -1.47% -1.49% 3.5M
|
Health Technology
|
| O: -0.17%
H: 0.76%
C: -3.42%
therapeutics growth study market
Axsome Therapeutics Presents New Data and Post-Hoc Analyses of Auvelity® in Patients with Major Depressive Disorder at the American College of Neuropsychopharmacology (ACNP) 2023 Annual Meeting
Published: 2023-12-11 (Crawled : 12:00) - globenewswire.com
AXSM | $67.91 3.33% 3.22% 890K
|
Health Technology
|
| O: -0.26%
H: 0.24%
C: -0.5%
auvelity meeting therapeutics
Axsome Therapeutics Hosts Solriamfetol Virtual Investor Event with Expert Thought Leaders Today
Published: 2023-12-07 (Crawled : 12:00) - globenewswire.com
AXSM | $67.91 3.33% 3.22% 890K
|
Health Technology
|
| O: 0.84%
H: 3.89%
C: 0.43%
therapeutics solriamfetol today
Axsome Therapeutics to Host Solriamfetol Virtual Investor Event on December 7
Published: 2023-11-22 (Crawled : 12:00) - globenewswire.com
AXSM | $67.91 3.33% 3.22% 890K
|
Health Technology
|
| O: 0.37%
H: 2.16%
C: 1.18%
therapeutics solriamfetol
Axsome Therapeutics to Present at the Piper Sandler 35th Annual Healthcare Conference
Published: 2023-11-21 (Crawled : 12:00) - globenewswire.com
AXSM | $67.91 3.33% 3.22% 890K
|
Health Technology
|
| O: -1.42%
H: 1.79%
C: -0.02%
conference therapeutics
Axsome Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update
Published: 2023-11-06 (Crawled : 12:00) - globenewswire.com
AXSM | $67.91 3.33% 3.22% 890K
|
Health Technology
|
| O: -4.67%
H: 10.55%
C: 0.52%
business update therapeutics financial results
Axsome Therapeutics and the Global Alzheimer’s Disease Community Come Together in Raising Support for the Millions Affected by This Illness During Alzheimer’s Disease Awareness Month 2023
Published: 2023-11-02 (Crawled : 11:00) - globenewswire.com
FNCTF | News | $11.0354 -20.84% 320
|
Communications
|
| O: 4.34%
H: 0.0%
C: 0.0%
AXSM | $67.91 3.33% 3.22% 890K
|
Health Technology
|
| O: 1.13%
H: 1.36%
C: -1.45%
disease alzheimer’s global therapeutics
Axsome Therapeutics to Present at Upcoming Investor Conferences
Published: 2023-10-31 (Crawled : 11:00) - globenewswire.com
AXSM | $67.91 3.33% 3.22% 890K
|
Health Technology
|
| O: 0.0%
H: 3.76%
C: 3.75%
therapeutics
Axsome Therapeutics Presents Results of the ACCORD trial of AXS-05 in Alzheimer’s Disease Agitation at the Clinical Trials on Alzheimer’s Disease (CTAD) 2023 Conference
Published: 2023-10-24 (Crawled : 11:00) - globenewswire.com
AXSM | $67.91 3.33% 3.22% 890K
|
Health Technology
|
| O: 1.98%
H: 2.15%
C: 0.76%
axs-05 conference disease alzheimer’s trials trial therapeutics results
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
AGBA | News | $1.26 215.0% 68.25% 130M
|
Finance
EGOX | $0.0515 43.06% 30.1% 330M
|
OLB 4 | $0.33 -14.95% 25.53% 840K
|
Technology Services
NVFY | $2.77 31.28% 23.83% 33M
|
Consumer Durables
ZCMD | $1.87 28.97% 22.46% 31M
|
Commercial Services
RCON | $0.1112 13.01% 21.28% 1.7M
|
Distribution Services
INSG | $3.03 25.21% 20.13% 330K
|
Electronic Technology
GCTK | $0.8191 22.25% 18.2% 190K
|
Manufacturing
WLGS | $0.59 18.0% 17.9% 2.3M
|
ASNS | $0.828 21.75% 17.86% 18K
|
Your saved searches
Save your searches and get alerts when important news are released.